title: [Treatment of bronchial asthma in adults. Current advances].
abstract: The last 20 years have shown an incredible improvement in the treatment of bronchial asthma, largely due to an earlier and more diffuse use of the inhaled glucocorticoids, that represent the pharmacological class of anti-asthma drugs more important to control the disease. Considering its efficacy and safety the current pharmacological treatment of asthma will probably remain unchanged for the next 10 years.
authors: Dipartimento di Medicina Clinica e Sperimentale, Centro di Ricerca su Asma e BPCO, Università, Ferrara. gaetano.caramori@unife.it
authors: Gaetano
authors: G
authors: Caramori
authors: Marco
authors: M
authors: Contoli
authors: Alberto
authors: A
authors: Papi
mesh_terms: D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D000069444:Omalizumab; D013806:Theophylline / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D020024:Leukotriene Antagonists; D000069444:Omalizumab; D013806:Theophylline